Jump to content

Levophacetoperane

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Ffffrr (talk | contribs) at 05:50, 10 April 2022 (Importing Wikidata short description: "Chemical compound" (Shortdesc helper)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Levophacetoperane
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • [(R)-phenyl-[(2R)-piperidin-2-yl]methyl] acetate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H19NO2
Molar mass233.311 g·mol−1
3D model (JSmol)
  • CC(=O)O[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2
  • InChI=1S/C14H19NO2/c1-11(16)17-14(12-7-3-2-4-8-12)13-9-5-6-10-15-13/h2-4,7-8,13-15H,5-6,9-10H2,1H3/t13-,14-/m1/s1
  • Key:BKPLVPRTTWIDNL-ZIAGYGMSSA-N
  (verify)

Levophacetoperane (Lidépran, Phacétoperane) is a psychostimulant developed by Rhône-Poulenc in the 1950s.[1] The drug has been used as an antidepressant and anorectic.[2][3] It is the reverse ester of methylphenidate.

See also

References

  1. ^ US 2928835, Marie JN, Michel JR, "New esters", published 15 March 1960, assigned to Rhône-Poulenc 
  2. ^ Delbeke FT, Debackere M (March 1975). "Isolation and detection of methylphenidate, phacetoperane and some other sympatomimetic central nervous stimulants with special reference to doping. I. Gas chromatographic detection procedure with electron capture detection for some secondary amines". Journal of Chromatography. 106 (2): 412–7. doi:10.1016/S0021-9673(00)93853-6. PMID 239015.
  3. ^ US 20150038533, Konofal E, Figadere B, "Phacetoperane for the treatment of attention-deficit hyperactivity disorder", published 5 February 2015, assigned to Assistance Publique – Hôpitaux de Paris